1206800-24-9 Usage
General Description
6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole is a chemical compound with complex structure, characterized by the presence of diverse functional groups. It includes a bromine atom, a fluorine atom embedded in the nitrophenyl group, and a methyl group attached to an indazole structure, which is a fused benzene and pyrazole ring. As a relatively rare and specialized compound, its specific use would be determined by the nature of reactions the various functional groups undergo. Because of its substituents and reactive moieties, this compound could likely serve as a reactant in the synthesis of more complex molecules, potentially for pharmaceuticals and bioactive compounds, but more information regarding its specific properties and uses is needed.
Check Digit Verification of cas no
The CAS Registry Mumber 1206800-24-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,6,8,0 and 0 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1206800-24:
(9*1)+(8*2)+(7*0)+(6*6)+(5*8)+(4*0)+(3*0)+(2*2)+(1*4)=109
109 % 10 = 9
So 1206800-24-9 is a valid CAS Registry Number.
InChI:InChI=1S/C14H9BrFN3O3/c1-18-12-6-10(15)14(4-8(12)7-17-18)22-13-3-2-9(19(20)21)5-11(13)16/h2-7H,1H3
1206800-24-9Relevant articles and documents
An Alternative Indazole Synthesis for Merestinib
Lu, Yu,Cole, Kevin P.,Fennell, Jared W.,Maloney, Todd D.,Mitchell, David,Subbiah, Ramesh,Ramadas, Balakumar
, p. 409 - 419 (2018)
A new synthesis of a key indazole-containing building block for the MET kinase inhibitor merestinib was designed and demonstrated. Crucial to the successful construction of the challenging indazole is an SNAr reaction, which forges the heterocy
Route design and development of a MET kinase inhibitor: A copper-catalyzed preparation of an N 1 - Methylindazole
Kallman, Neil J.,Liu, Chin,Yates, Matthew H.,Linder, Ryan J.,Ruble, J. Craig,Kogut, Eugene F.,Patterson, Lawrence E.,Laird, Dana L. T.,Hansen, Marvin M.
, p. 501 - 510 (2014/05/06)
The synthesis of a MET kinase inhibitor in an overall yield of 22% was achieved over eight steps starting with 3-hydroxybenzaldehyde, an improvement from the initial 12-step process with a 5.4% yield. Highlights of the process chemistry design and development are a Cu-catalyzed cyclization to form an important N1-methylindazole ring, a selective nitro reduction in the presence of an aryl bromide, a late-stage Suzuki cross-coupling, and a base-promoted Boc deprotection to form the desired drug candidate.
